1933 Industries (TGIF) AI Stock Analysis

• Market Cap: C$2.45M
• Dividend Yield: N/A
• Average Volume (3M): 247.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.06
• Revenue Growth: -9.20%
• EPS Growth: 93.62%
• Country: CA
• Employees: 85
• Sector: Healthcare
• Sector Strength: 64
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 490,471,650
• 10 Day Avg. Volume: 476,691
• 30 Day Avg. Volume: 247,240
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.12
• Price to Cash Flow (P/CF): 1.80
• P/FCF Ratio: 6.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall score reflects significant financial performance challenges, with declining revenues and high financial leverage being major concerns. Technical analysis indicators are limited, and valuation metrics also suggest caution. Corporate events, while aiming to improve financial flexibility, have a neutral impact. The company needs to address financial instability and improve profitability to enhance its outlook.

1933 Industries Business Overview & Revenue Model

Company Description

1933 Industries Inc. (TGIF) is a vertically integrated cannabis company operating in the United States. The company specializes in the cultivation, production, and distribution of cannabis products, including both recreational and medicinal offerings. Its core products include cannabis flower, concentrates, and infused products, and it is known for its diverse portfolio of brands catering to different market segments.

How the Company Makes Money

1933 Industries generates revenue through a multi-faceted business model that includes the sale of cannabis products and branded goods. The company operates cultivation facilities to produce high-quality cannabis flower and uses this raw material to create a range of products, including concentrates, edibles, and topicals. It sells these products through both wholesale and retail channels, targeting dispensaries and end consumers. Additionally, 1933 Industries collaborates with other brands and engages in licensing agreements to expand its product offerings and market reach. These partnerships and the company's integrated supply chain contribute significantly to its earnings by ensuring product availability and brand presence in key markets.

1933 Industries Financial Statement Overview

Summary

1933 Industries faces financial difficulties with ongoing losses and negative equity. Some progress is seen in revenue growth and cash flow generation, but substantial improvements are needed in profitability and balance sheet stability.

Income Statement

1933 Industries shows some improvement in revenue with a growth rate of 5.9% from the previous year. However, profitability remains a challenge with a net loss, no positive EBIT, and a low EBITDA margin of 1.6%. The gross profit margin improved to 15.2%, but the overall financial health remains weak due to continued losses.

Balance Sheet

The balance sheet reflects significant financial instability with negative stockholders' equity, indicating potential insolvency issues. The debt-to-equity ratio is not applicable due to negative equity, but the high total debt relative to assets shows a risky leverage position. The equity ratio is negative, further highlighting financial distress.

Cash Flow

The company has managed to generate positive operating cash flow, showing some operational improvements. Free cash flow turned positive, reflecting better cash management. However, the operating cash flow to net income ratio indicates challenges in translating operational activities into profitability.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
17.50M	19.35M	18.27M	12.54M	11.98M	11.96M
	Gross Profit
1.90M	2.94M	-4.22M	2.69M	4.82M	2.28M
	EBIT
1.90M	0.00	-9.64M	-4.81M	-3.32M	-16.63M
	EBITDA
695.77K	313.67K	-10.03M	-13.83M	-2.71M	-14.26M
	Net Income Common Stockholders
-889.79K	-1.14M	-13.36M	-18.07M	-6.29M	-20.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
318.57K	449.18K	1.09M	363.27K	4.41M	2.76M
	Total Assets
17.05M	16.87M	18.02M	29.01M	45.35M	46.58M
	Total Debt
17.79M	16.78M	17.57M	17.68M	17.87M	25.74M
	Net Debt
17.47M	16.33M	16.48M	17.32M	13.47M	22.98M
	Total Liabilities
22.61M	21.70M	23.28M	21.49M	20.12M	27.13M
	Stockholders Equity
-4.41M	-3.53M	-3.69M	8.52M	25.99M	20.36M
Cash Flow		Free Cash Flow
1.20M	801.71K	-2.33M	-5.10M	-5.12M	-16.07M
	Operating Cash Flow
1.69M	1.69M	-1.53M	-5.09M	-4.67M	-14.98M
	Investing Cash Flow
-381.39K	-890.78K	2.33M	1.58K	-456.36K	-1.24M
	Financing Cash Flow
-1.48M	-1.46M	-266.55K	1.53M	6.06M	1.05M

1933 Industries Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACB	55 Neutral	$325.46M	25.51	4.78%	―	16.39%	-98.10%
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
OGI	48 Neutral	$184.33M	―	-18.27%	―	7.33%	84.41%
TGIF	44 Neutral	C$2.45M	―		―	-9.20%	93.62%
WEED	44 Neutral	$264.39M	―	-84.50%	―	-16.27%	―

1933 Industries Corporate Events

Zentek Launches US$30 Million At-The-Market Offering in U.S.

Zentek Ltd. has announced a US$30 million at-the-market offering in the United States, with Rodman & Renshaw LLC as the exclusive sales agent. The offering will be conducted on Nasdaq and other U.S. marketplaces, with proceeds intended for corporate purposes. This move is expected to enhance Zentek’s financial flexibility and support its growth strategy.

1933 Industries Reports Q1 2025 Financial Results Amid Market Challenges

1933 Industries reported its first quarter financial results for 2025, showing a revenue of $4.0 million, a decrease from the previous year’s $5.2 million, attributed to soft sales and declining flower prices in Nevada. Despite a net loss of $0.6 million, the company maintained a strong market position, ranking third in cannabis sales in Nevada, reflecting its continued influence in the market despite economic challenges.

1933 Industries Appoints New CFO and VP Finance

1933 Industries has announced the appointment of Mr. Jeremy Fong as the new Chief Financial Officer and Ms. Kathy Estochin as VP Finance and Administration, effective February 1, 2025. Mr. Fong brings significant financial and auditing experience, while Ms. Estochin, who has been with the company since 2020, has been elevated due to her extensive contributions. These leadership changes, along with the roles of Ms. Ester Vigil and interim CEO Mr. Brian Farrell, are poised to drive the company’s strategic development and operational goals.

1933 Industries Faces Filing Delays and Regulatory Orders

1933 Industries has announced a delay in the filing of its audited financial statements for the year ended July 31, 2024, resulting in a management cease trade order (MCTO) granted by the British Columbia Securities Commission. The company expects to complete the filings by February 2025, lifting the anticipated Cease Trade Order, while confirming no material changes or insolvency issues have arisen since their prior announcement.